ArticleEBioMedicine2020
Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Integrated identification of key immune related genes and patterns of immune infiltration in calcified aortic valvular disease: A network based meta-analysis.Frontiers in genetics · 2022Pooled it
- Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.Frontiers in immunology · 2022Pooled it
- Profiling tumor immune microenvironment of epithelial ovarian carcinoma.Oncoimmunology · 2026Article
- Tumour immune cell infiltration and response to FOLFOX or FOLFIRI chemotherapy in colorectal cancer.The pharmacogenomics journal · 2026Article
- The role of tumor-associated macrophages in cancer development and their significance as prognostic markers.Clinical and experimental medicine · 2026Review
- Single-Cell Transcriptomic Atlas of Chicken Ovarian Aging and Cancer Drives Prognostic Model Development.Cancers · 2026Article
- Differentiation and mitochondrial metabolic characteristics of CD8Cancer immunology, immunotherapy : CII · 2025Article
- CYBB as a potential therapeutic target through influencing ferroptosis and macrophage in ovarian cancer.Discover oncology · 2025Article
- AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.Breast cancer research : BCR · 2025Article
- Composite score of PD-1Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer.Frontiers in immunology · 2025Article
- Spatial tumor immune microenvironment phenotypes in ovarian cancer.NPJ precision oncology · 2024Article
- Immune cell landscapes are associated with high-grade serous ovarian cancer survival.Scientific reports · 2024Article
- Article
- Dual Role ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Identification of glycosyltransferase-related genes signature and integrative analyses in patients with ovarian cancer.American journal of clinical and experimental immunology · 2024Article
- Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9.Biomolecules · 2023Article
- Association of Tumor Cell Metabolic Subtype and Immune Response With the Clinical Course of Hepatocellular Carcinoma.The oncologist · 2023Article
- Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.International journal of molecular sciences · 2023Article
- CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.Cancer immunology, immunotherapy : CII · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing evidence supports that the immune infiltration of tumours is associated with prognosis. Here, we sought to assess the relevance of the cellular composition of the immune infiltrate to survival after platinum-based chemotherapy amongst patients with high-grade serous ovarian cancer and evaluate these effects by molecular subtype.
methodsWe searched publicly available databases and identified 13 studies with more than 2000 patients. We estimated the proportions of 22 immune cell subsets by using a computational approach (CIBERSORT). Then, we investigated the associations between each immune cell subset and progression-free survival (PFS) and overall survival (OS), with cellular proportions modelled as quartiles.
findingsA high fraction of M1 [hazard ratio (HR) = 0.92, 95% confidence interval (CI) = 0.86-0.99] and M0 (HR = 0.93, 95% CI = 0.87-0.99) macrophages emerged as the most closely associated with favourable OS. Neutrophils were associated with poor OS (HR = 1.06, 95% CI = 1.00-1.13) and PFS (HR = 1.10, 95% CI = 1.02-1.13). Amongst the immunoreactive tumours, the M0 macrophages and the CD8+ T cells were associated with improved OS, whereas the M2 macrophages conferred worse OS. Interestingly, PD-1 was associated with good OS (HR=0.89, 95% CI = 0.80-1.00) and PFS (HR=0.89, 95% CI = 0.79-1.01) in this subtype. Four subgroups of tumours with distinct survival patterns were identified using immune cell proportions with unsupervised clustering.
interpretationFurther investigations of the quantitative cellular immune infiltrations in tumours may contribute to therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.